Cantargia, a biopharma spin-out of Lund University, raises SEK 7m from Sunstone Capital and LU Bioscience to fight leukaemia.

Lund University spin-out Cantargia, which is development therapeutics to treat leukaemia, has raised SEK 7m ($1m). Venture firm Sunstone Capital invested €500k ($638k) in the Sweden-based biopharmaceutical firm, and LU Bioscience (LUBio), a holding company partially owned (20%) by Lund University, made up the difference with a further SEK 3m. Following the investment, Sunstone and…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.